Venetoclax

In this article, we will discuss Venetoclax (Dosage Overview). So, let’s get started.

Venetoclax is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory trial.

Dosage

Patient Selection

Select patients for the treatment of relapsed or refractory CLL with Venetoclax based on the presence of 17p deletions in blood specimens. Patients without 17p deletion at diagnosis should be retested at relapse because acquisition of 17p deletion can occur.

Recommended Dosage

Assess patient-specific factors for level of risk of tumor lysis syndrome (TLS) and provide prophylactic hydration and anti-hyperuricemics to patients prior to first dose of Venetoclax to reduce risk of TLS. Administer the Venetoclax dose according to a weekly ramp-up schedule over 5 weeks to the recommended daily dose of 400 mg. The 5-week ramp-up dosing schedule is designed to gradually reduce tumor burden (debulk) and decrease the risk of TLS.

• Initiate therapy with Venetoclax at 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg.
• Venetoclax tablets should be taken orally once daily with a meal and water. Do not chew, crush, or break tablets.
• Perform prophylaxis for tumor lysis syndrome.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.